“A Clinical Study to evaluate efficacy of Unani Formulation in Benign Prostatic Hyperplasia

“A Clinical Study on the Management of Benign Prostatic Hyperplasia with a Unani Polyherbal Formulation An open label single Arm Trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/057510

Enrollment

Registered

2023-09-12

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: Extract of unani polyherbal formulation of karonda (carrisa carandas),Khar khasak (Tribulus terristris linn),Mako(Solanum nigrum linn),Beekh-e-kasni(Chichorium intybus),Bhui Amla (Phyll

Eligibility

Inclusion criteria

Inclusion criteria: Daignosed cases of Benign Prostatic Hyperplasia on digital rectal examination and USG, Volume of prostate 30-60ml,International Prostate symptoms score(IPSS)1-19, PSA less than 4ng/ml, Patient unwilling to sign the consent form.

Exclusion criteria

Exclusion criteria: Bladder stones , Stricture Urethra, Renal & Hepatic Failure Malignancy, Patient unwilling to sign the consent form.

Design outcomes

Primary

Measure	Time frame
volume & weight of prostate gland, postvoid residual urine volumeTimepoint: volume & weight of prostate gland, postvoid residual urine volume	—

Secondary

Measure	Time frame
straining, urgency , hesitency, incomplete emptying,frequency, weak stream,nocturia & quality of life of the patient will be assesedTimepoint: 12 weeks	—

Countries

India

Contacts

Public ContactDr Mohd Faizan

Ayurvedic and Unani Tibbia College Hospital

drrahman002@gmail.com9313980776

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026